All articles by sayeeda nasreen

sayeeda nasreen

Repare reports data from Phase I solid tumours therapy trial

The Lunresertib programme also includes Module 2 which will evaluate lunresertib along with camonsertib.

Ventyx completes enrolment in ulcerative colitis and plaque psoriasis trials

Topline results from both the trials are expected in the fourth quarter of this year.

Immune-Onc announces dose escalation data from leukaemia therapy trial

IO-202 was well-tolerated in the study and no dose-limiting toxicities were observed.

Vera initiates Phase III study of kidney disease therapy

Change in proteinuria as evaluated by urine protein to creatinine ratio at week 36 is the primary endpoint.

DURECT concludes patient enrolment in Phase IIb trial of AH therapy

Patients were enrolled from more than 60 sites across Australia, the UK, EU, and the US.

Emergex reports positive outcomes from naNO-DENGUE Phase I trial

Participants were enrolled at the Centre for Primary Care and Public Health in Lausanne, Switzerland.

FibroGen’s study of DMD therapy fails to meet primary endpoint

Pamrevlumab was found to be well tolerated and safe, with mild or moderate treatment emergent adverse events.

CIRM awards grant to support Eureka’s T-cell therapy trial

The ongoing ARYA-2 study is part of the company’s liver cancer portfolio.

Oncternal doses first patient in trial of B cell lymphoma therapy

Initial data from the trial is expected late this year, with additional clinical data readouts anticipated in the next year.

LianBio reports positive topline data from gastric cancer therapy trial

An ORR of 25% was observed in the gastroesophageal junction adenocarcinoma and gastric cancer treated group.